Oppenheimer & Co. Inc. Invests $315,000 in Solventum Co. (NYSE:SOLV)

Oppenheimer & Co. Inc. acquired a new stake in shares of Solventum Co. (NYSE:SOLV) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,524 shares of the company’s stock, valued at approximately $315,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of SOLV. Price T Rowe Associates Inc. MD bought a new position in shares of Solventum during the first quarter valued at approximately $5,889,000. CWM LLC acquired a new stake in Solventum in the second quarter worth $473,000. Great Valley Advisor Group Inc. bought a new stake in Solventum in the second quarter valued at $493,000. First Horizon Advisors Inc. acquired a new position in shares of Solventum during the second quarter valued at $58,000. Finally, Swedbank AB bought a new position in shares of Solventum during the second quarter worth about $4,711,000.

Solventum Stock Up 1.8 %

SOLV opened at $69.63 on Friday. The business has a 50 day moving average price of $70.51 and a two-hundred day moving average price of $62.31. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05.

Analysts Set New Price Targets

SOLV has been the topic of several recent research reports. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating on the stock. BTIG Research began coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. Morgan Stanley increased their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Piper Sandler lifted their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus initiated coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.